Where Reviva Pharmaceuticals Stands With Analysts
Portfolio Pulse from Benzinga Insights
In the last quarter, Reviva Pharmaceuticals (NASDAQ: RVPH) received 3 bullish and 1 somewhat bullish analyst ratings. The company has an average 12-month price target of $16.25, with a high of $20.00 and a low of $10.00. The average price target has increased by 62.5% over the past month.
June 08, 2023 | 1:02 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Reviva Pharmaceuticals received positive analyst ratings in the last quarter, with an average 12-month price target of $16.25, which has increased by 62.5% over the past month.
The positive analyst ratings and the significant increase in the average 12-month price target over the past month indicate a bullish sentiment towards Reviva Pharmaceuticals. This could lead to a short-term increase in the stock price as investors may see the positive ratings as a sign of the company's potential growth and performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100